FDA Inspection
Hikma Pharmaceuticals USA Inc.Hikma Pharmaceuticals USA Inc. – FDA Inspection, Nov 3, 2023
Record Details
This FDA Inspection record concerns Hikma Pharmaceuticals USA Inc., with an inspection on November 3, 2023, covering drugs.
- Inspection Date
- November 3, 2023
- Product Type
- Drugs
View Company Profile
ID · e7b030d5-aa1b-472b-8874-97ba0cb35d84
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1222115
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
5- 21 CFR 211.160(b)(3)Drug product sample
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
- 21 CFR 211.84(d)(1)Component identity verification
- 21 CFR 314.81(b)(1)(ii)Contamination, chemical or physical change, deterioration
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Hikma Pharmaceuticals USA Inc.
18| Date | Classification | Office | Project area |
|---|---|---|---|
| May 13, 2026 | Not classified | New Jersey District Office | |
| June 12, 2024 | VAI | Drug Quality Assurance | |
| July 7, 2022 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 10, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| September 14, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Hikma Pharmaceuticals USA Inc.
- FDA Inspection 1304368 - 2026-05-13
- FDA Inspection 1237333 - 2024-06-12
- FDA Inspection 1176451 - 2022-07-07
- FDA Inspection 1106822 - 2019-09-10
- FDA Inspection 1067645 - 2018-09-14
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.